Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0M2MR
|
|||
| Former ID |
DAP000522
|
|||
| Drug Name |
Gliclazide
|
|||
| Synonyms |
Diaikron; Diamicron; Gliclazida; Gliclazidum; Gliklazid; Glimicron; Glyclazide; Nordialex; S 1702; S 852; SE 1702; Diamicron (TN); Dianorm (TN); Gliclazida [INN-Spanish]; Gliclazidum [INN-Latin]; Glimicron (TN); S-1702; S-852; Gliclazide (JAN/INN); Glubitor-OD (TN); Gliclazide [BAN:INN:DCF:JAN]; N-(hexahydrocyclopenta[c]pyrrol-2(1H)-ylcarbamoyl)-4-methylbenzenesulfonamide; N-[(hexahydrocyclopenta[c]pyrrol-2(1H)-ylamino)carbonyl]-4-methylbenzenesulfonamide; N-(4-Methylbenzenesulfonyl)-N'-(3-azabicyclo(3.3.0)oct-3-yl)urea; 1-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)-3-(4-methylphenyl)sulfonylurea; 1-(3-Azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea; 1-(3-Azabicyclo[3.3.0]oct-3-yl)-3-p-tolylsulphonylurea; 1-(Hexahydrocyclopenta(c)pyrrol-2(1H)-yl)-3-(p-tolylsulfonyl)urea
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diabetic complication [ICD-11: 5A2Y; ICD-9: 253.5, 588.1] | Approved | [1] | |
| Therapeutic Class |
Hypoglycemic Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H21N3O3S
|
|||
| Canonical SMILES |
CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2
|
|||
| InChI |
1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19)
|
|||
| InChIKey |
BOVGTQGAOIONJV-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 21187-98-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
3206372, 5035155, 7848662, 7979407, 8152209, 10321809, 11342141, 11362324, 11364372, 11366934, 11369496, 11372903, 11374235, 11377658, 11466586, 11467706, 11486292, 11487726, 11491677, 11492413, 11495292, 11533945, 14826273, 24895090, 26612635, 26612723, 26748918, 26748919, 26748920, 29222608, 47656599, 47730748, 48179242, 48179243, 48328563, 48403959, 48416054, 49646130, 49698833, 50061218, 50086570, 50107481, 50107482, 50107483, 50880518, 57321824, 81040947, 81066070, 81093129, 85280584
|
|||
| ChEBI ID |
CHEBI:31654
|
|||
| ADReCS Drug ID | BADD_D01022 | |||
| SuperDrug ATC ID |
A10BB09
|
|||
| SuperDrug CAS ID |
cas=021187984
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides dorei DSM 17855
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Gliclazide can be metabolized by Bacteroides dorei DSM 17855 (log2FC = -0.491; p = 0.026). | |||
|
Studied Microbe: Bacteroides fragilis ATCC43859
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Gliclazide can be metabolized by Bacteroides fragilis ATCC43859 (log2FC = -0.582; p = 0.008). | |||
|
Studied Microbe: Bacteroides fragilis HMW 610
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Gliclazide can be metabolized by Bacteroides fragilis HMW 610 (log2FC = -0.498; p = 0.045). | |||
|
Studied Microbe: Bacteroides fragilis HMW 615
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Gliclazide can be metabolized by Bacteroides fragilis HMW 615 (log2FC = -0.438; p = 0.018). | |||
|
Studied Microbe: Bacteroides fragilis str. 3397 T10
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Gliclazide can be metabolized by Bacteroides fragilis str. 3397 T10 (log2FC = -0.473; p = 0.019). | |||
|
Studied Microbe: Bacteroides fragilis str. DS-208
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Gliclazide can be metabolized by Bacteroides fragilis str. DS-208 (log2FC = -0.423; p = 0.009). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron 3731
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Gliclazide can be metabolized by Bacteroides thetaiotaomicron 3731 (log2FC = -0.45; p = 0.011). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron 7330
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Gliclazide can be metabolized by Bacteroides thetaiotaomicron 7330 (log2FC = -0.441; p = 0.003). | |||
|
Studied Microbe: Bacteroides vulgatus ATCC 8482
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Gliclazide can be metabolized by Bacteroides vulgatus ATCC 8482 (log2FC = -0.578; p = 0.021). | |||
|
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Gliclazide can be metabolized by Odoribacter splanchnicus (log2FC = -0.411; p = 0.019). | |||
|
Studied Microbe: Parabacteroides distasonis ATCC 8503
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Gliclazide can be metabolized by Parabacteroides distasonis ATCC 8503 (log2FC = -0.375; p = 0.005). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | ATP-binding cassette transporter C8 (ABCC8) | Target Info | Blocker | [3], [4] |
| KEGG Pathway | ABC transporters | |||
| Insulin secretion | ||||
| Type II diabetes mellitus | ||||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Pancreas Function | ||||
| Pathway Interaction Database | FOXA2 and FOXA3 transcription factor networks | |||
| Reactome | ABC-family proteins mediated transport | |||
| Regulation of insulin secretion | ||||
| WikiPathways | Potassium Channels | |||
| Integration of energy metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Cefradine - FDA approved drug information (drug label) from DailyMed. | |||
| REF 2 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 3 | Structural basis for the interference between nicorandil and sulfonylurea action. Diabetes. 2001 Oct;50(10):2253-9. | |||
| REF 4 | Pharmacological modulation of K(ATP) channels. Biochem Soc Trans. 2002 Apr;30(2):333-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.